1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015. CA Cancer J Clin.2016,66:115-132. 2 细胞色素P4502D6基因多态性和药物相互作用。中国临床药理学与治疗学,2006,11:369-374. 3 Benny K,Adithan C.Genetic polymorphism of CYP2D6. Indian J Pharmacol,2001,3:147-169. 4 Zanger UM,Fischer J,Raimundo S,et al.Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics,2001,11:573-585. 5 Osborne CK.Adjuvant endocrine therapy EA//Harris LM.Diseases of the breast.3rd Ed.USA.Lippincott:Williams＆Wilkins,2004:865-891. 6 Owsley J,Jimeno A,Diamond JR.Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.Drugs Today(Barc),2016,52:119-129. 7 Chirgwin JH,Giobbie-Hurder A,Coates AS,et al.Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole,alone and in sequence.J Clin Oncol,2016,34:2452-2459. 8 Rondón-Lagos M,Rangel N,Di Cantogno LV,et al.Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes.Endocr Relat cancer,2016,23:635-650. 9 Hayes DF,Stearns V,Rae J,et al.A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients.J Natl Cancer Inst,2008,100:610-613. 10 Watanabe M,Watanabe N,Maruyama S,et al.Comparative metabolic study between two selective estrogen receptor modulators,toremifene and tamoxifen,in human liver microsomes.Drug Metab Pharmacokinet,2015,30:325-333. 11 Romero-Lorca A,Novillo A,Gaibar M,et al.Impacts of the glucuronidase genotypes UGT1A4,UGT2B7,UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients.PLoS One,2015,10:e0132269.
